Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.

Poloxime (100 μM) suppresses phosphopeptide binding to the polo-box domain (PBD) of polo-like kinase 1 [2].

17302-61-3

C10H13NO2

179.22

DMSO:100 mg/mL (557.97 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years